Astra Drug Improves Survival by Half in Early Stage Lung Cancer

A blockbuster lung cancer drug from AstraZeneca Plc was found to improve survival by more than half in a subset of patients, boosting the company’s ambitions to widen its oncology portfolio across as many groups and indications as possible.

Tagrisso, Astra’s best-selling drug, reduced the risk of death in patients with an early-stage type of non-small cell lung cancer after tumor removal by 51%, according to results released at the American Society of Clinical Oncology in Chicago Sunday. The drug is already approved for use in the category, known as epidermal growth factor receptor-mutated NSCLC, but the results could boost ...